

CLAIMS

1. A pharmaceutical combination comprising:

(A) an anti-LY75 antibody, or an antigen-binding portion thereof, said antibody or portion thereof comprising:

a) a heavy chain variable region comprising:

i) a first vhCDR comprising SEQ ID NO: 5;

ii) a second vhCDR comprising SEQ ID NO: 6; and

iii) a third vhCDR comprising SEQ ID NO: 7; and

b) a light chain variable region comprising:

i) a first vlCDR comprising SEQ ID NO: 8;

ii) a second vlCDR comprising SEQ ID NO: 9; and

iii) a third vlCDR comprising SEQ ID NO: 10;

~~optionally wherein any one or more of the above SEQ ID NOs independently comprise one or two amino acid substitutions,~~

wherein the anti-LY75 antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety, and wherein said moiety is a drug; and

(B) Rituximab;

wherein the pharmaceutical combination is in the form of a combined preparation for simultaneous, separate or sequential use.

2. The pharmaceutical combination as claimed in claim 1, wherein ~~any one or more of SEQ ID NOs: 5-10 independently comprise one or two conservative amino acid substitutions~~ the antibody or antigen-binding portion thereof is capable of being internalised.

3. The pharmaceutical combination as claimed in ~~claim 1 or claim 2, wherein the antibody or antigen-binding portion thereof is capable of being internalised.~~

~~4. The pharmaceutical combination as claimed in~~ any one of claims 1 to 3, wherein the anti-LY75 antibody or an antigen-binding portion thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to

SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2.

54. The pharmaceutical combination as claimed in any one of claims 1 to 43, wherein the anti-LY75 antibody is a human IgG1 monoclonal antibody.

65. The pharmaceutical combination according to any one of claims 1 to 4, wherein said drug is a maytansinoid.

6. The pharmaceutical combination according to claim 5, wherein said drug is a maytansinoid or a derivative thereof. DM4 or DM1.

7. The pharmaceutical combination according to claim 6, wherein said drug is DM4 or DM1.

8. The pharmaceutical combination according to any one of claims 1 to 7, wherein (A) and/or (B) additionally comprise one or more pharmaceutically-acceptable diluents, excipients or carriers.

98. A kit comprising:

- (i) an expression vector comprising DNA encoding the heavy and light chains of the anti-LY75 antibody or antigen-binding portion thereof of claim 1; and
- (ii) an expression vector comprising DNA encoding the heavy and light chains of Rituximab.

109. A host cell comprising expression vectors comprising nucleic acids encoding:

- (i) the heavy chain of the anti-LY75 antibody or antigen-binding portion thereof of claim 1;
- (ii) the light chain of the anti-LY75 antibody or antigen-binding portion thereof of claim 1;
- (iii) the heavy chain of Rituximab; and
- (iv) the light chain of Rituximab.

1110. A pharmaceutical combination according to any one of claims 1 to 87, for use in the treatment of cancer, wherein components (A) and (B) are simultaneously, separately or sequentially administered to the patient for the treatment of the cancer diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.

~~1211.~~ The pharmaceutical combination for use according to claim ~~1110~~, wherein the anti-LY75 antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.

~~1312.~~ The pharmaceutical combination for use according to claim ~~1110~~ or claim ~~1211~~, wherein the covalently-attached drug is a maytansinoid.

~~1413.~~ The pharmaceutical combination for use according to claim ~~1312~~, wherein the maytansinoid is DM4.

~~15. — The pharmaceutical combination for use according to any one of claims 11 to 14, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.~~

~~1614.~~ Use of components (A) and (B) of the pharmaceutical combination as defined in any one of claims 1 to ~~87~~ in the manufacture of a pharmaceutical combination for simultaneous, separate or sequential use for the treatment of ~~cancer~~ diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.

~~1715.~~ The use according to claim ~~1614~~, wherein the anti-LY75 antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.

~~1816.~~ The use according to claim ~~1614~~ or claim ~~1715~~, wherein the covalently-attached drug is a maytansinoid.

~~1917.~~ The use according to claim ~~1816~~, wherein the maytansinoid is DM4.

~~20. — The use according to any one of claims 16 to 19, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.~~

~~2118.~~ A pharmaceutical combination according to any one of claims 1 to ~~87~~ for use in therapy or for use as a medicament.